BUILDING A PRODUCT PIPELINE – ESTABLISHING THE COMMERCIAL POTENTIAL OF NEW PRODUCTS

建立产品管道 — 确立新产品的商业潜力

• 批准号: 130995
• 金额: $ 19.11万
• 依托单位: ABSYNTH BIOLOGICS LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=130995
• 关键词: BUILDING; PRODUCT; PIPELINE; ESTABLISHING; COMMERCIAL

Absynth has an innovative approach for developing antibacterial vaccines and antibodies, based on a means of identifying novel protein antigens that harness the immune system and work by a novel dual-action mechanism. The need for these products is in part due to the spread of antibiotic resistant strains. Proof of principle has been achieved with protection against Staphylococcus aureus, a pathogen that causes life-threatening infections in hospitals and the community. A central aspect of Absynth’s technology is conservation of the protein antigens across the major bacterial pathogens - the same targets found in S. aureus are present in many other bacterial species. Having completed an assessment of the broader market opportunity, funded by the TSB, Absynth now plans to perform experimental validation of vaccines targeting two other bacterial pathogens, Clostridium difficile and Streptococcus pyogenes to establish the product potential.

Absynth拥有一种开发抗菌疫苗和抗体的创新方法，该方法基于识别利用免疫系统并通过新型双重作用机制工作的新型蛋白质抗原的方法。对这些产品的需求部分是由于抗生素耐药菌株的传播。通过防止金黄色葡萄球菌，一种在医院和社区引起危及生命的感染的病原体，已经实现了原则的证明。Absynth技术的一个核心方面是在主要的细菌病原体中保存蛋白质抗原-在S.金黄色葡萄球菌存在于许多其他细菌物种中。在完成了对TSB资助的更广泛市场机会的评估后，Absynth现在计划对针对其他两种细菌病原体（艰难梭菌和化脓性链球菌）的疫苗进行实验验证，以确定产品潜力。